MSB.AX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (1 liep. 2024 @ 09:10):
Our systems believe the stock currently is undervalued by 0.47% compare to its pairs and should correct upwards.

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland...

Stats
Šios dienos apimtis	8.82M
Vidutinė apimtis	10.84M
Rinkos kapitalizacija	1.14B
EPS	$-0.0191 ( Q2 \| 2023-12-31 )
Kita pelno data	( $0 ) 2024-07-29
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-8.33 (Sector) 0 (Industry) 0
ATR14	$0.00400 (0.40%)

ACW.AX 4.84%

ADO.AX 5.00%

AGH.AX 4.35%

ANP.AX -4.92%

ATH.AX 25.00%

AVE.AX -33.33%

BIT.AX 2.63%

BNO.AX -10.00%

BOT.AX -8.70%

CAN.AX 7.14%

CPH.AX 0.00%

CSL.AX -0.88%

CTE.AX 0.81%

CUV.AX -0.65%

CYP.AX 0.00%

DXB.AX 3.92%

ECS.AX 5.88%

EOF.AX -6.67%

GSS.AX 5.56%

IDT.AX -4.55%

IMC.AX -5.68%

IMM.AX 5.08%

IMU.AX -3.51%

IXC.AX 0.00%

KZA.AX 9.59%

LCT.AX 7.14%

LGP.AX 5.26%

MSB.AX 1.01%

MVP.AX -2.47%

MXC.AX 2.44%

NEU.AX -4.98%

NOX.AX 0.00%

NSB.AX 0.00%

OCC.AX 2.82%

OPT.AX -1.43%

OSL.AX 25.00%

PAA.AX 0.00%

PAB.AX 14.29%

PAR.AX 13.73%

PBP.AX 0.00%

PIQ.AX -1.14%

PTX.AX 5.26%

PXS.AX 3.70%

PYC.AX 0.00%

RAC.AX -0.27%

RCE.AX 5.26%

SPL.AX -3.16%

TLX.AX -3.00%

VBS.AX -1.30%

Koreliacija (AI algo v.1.1b): Undervalued: 0.47% $1.010 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: 0.12 (neutral)

Trumpas: 0.12 (neutral)

Signal:(58.819) Neutral

Mesoblast Ltd Koreliacija

10 Labiausiai teigiamai susiję koreliacijos

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

Mesoblast Ltd Koreliacija - Valiuta/Žaliavos

0.29
( neutral )

-0.64
( weak negative )

0.00
( neutral )

0.04
( neutral )

0.00
( neutral )

0.41
( neutral )

Mesoblast Ltd Finansinės ataskaitos

Annual	2023
Pajamos:	$7.50M
Bruto pelnas:	$-47.42M (-632.20 %)
EPS:	$-0.110

FY	2023
Pajamos:	$7.50M
Bruto pelnas:	$-47.42M (-632.20 %)
EPS:	$-0.110

FY	2023
Pajamos:	$0
Bruto pelnas:	$0 (0.00 %)
EPS:	$0

FY	2022
Pajamos:	$10.21M
Bruto pelnas:	$-53.36M (-522.58 %)
EPS:	$-0.140

Financial Reports:

No articles found.

Mesoblast Ltd Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Mesoblast Ltd

Mesoblast Limited engages in the development of regenerative medicine products in Australia, the United States, Singapore, the United Kingdom, and Switzerland. The company offers products in the areas of cardiovascular, spine orthopedic disorder, oncology, hematology, and immune-mediated and inflammatory diseases. Its proprietary regenerative medicine technology platform is based on specialized cells known as mesenchymal lineage cells. The company offers Remestemcel-L that is in Phase III clinical trials for the treatment of systemic inflammatory diseases, including steroid refractory acute graft versus host disease, acute respiratory distress syndrome, and biologic refractory inflammatory bowel disease; and Remestemcel-L, which is in Phase III clinical trials to treat chronic heart failure and chronic low back pain due to degenerative disc disease. It is also developing MPC-300-IV to treat biologic refractory rheumatoid arthritis diabetic nephropathy; and MPC-25-IC for the treatment or prevention of acute myocardial infarction. The company has strategic partnerships with Tasly Pharmaceutical Group to offer MPC-150-IM for heart failure and MPC-25-IC for heart attacks in China; JCR Pharmaceuticals Co. Ltd. to treat wound healing in patients with epidermolysis bullosa; and Grünenthal to develops and commercializes cell therapy for the treatment of chronic low back pain. Mesoblast Limited was incorporated in 2004 and is headquartered in Melbourne, Australia.